The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N-(4-morpholinophenyl)-5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine ID: ALA1956687
PubChem CID: 135979614
Max Phase: Preclinical
Molecular Formula: C18H18N8O
Molecular Weight: 362.40
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: c1nc2c(Nc3ccc(N4CCOCC4)cc3)ncc(-c3cn[nH]c3)n2n1
Standard InChI: InChI=1S/C18H18N8O/c1-3-15(25-5-7-27-8-6-25)4-2-14(1)24-17-18-20-12-23-26(18)16(11-19-17)13-9-21-22-10-13/h1-4,9-12H,5-8H2,(H,19,24)(H,21,22)
Standard InChI Key: WSPYBPVYCFYIRM-UHFFFAOYSA-N
Molfile:
RDKit 2D
27 31 0 0 0 0 0 0 0 0999 V2000
1.8150 -0.3575 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5326 0.0565 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.5297 0.8884 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8132 1.2981 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0991 0.0561 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.1004 0.8863 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.3112 1.1440 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.1779 0.4730 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3092 -0.1992 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.8148 -1.1837 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.5247 -1.5942 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5215 -2.4153 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2306 -2.8256 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9419 -2.4160 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9398 -1.5917 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2301 -1.1850 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6578 -2.8286 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.6558 -3.6522 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.3675 -4.0647 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0853 -3.6546 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.0867 -2.8273 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.3703 -2.4102 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8114 2.1244 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4825 2.6138 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.2254 3.3991 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.3991 3.3973 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.1456 2.6109 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12 13 1 0
2 3 1 0
13 14 2 0
14 15 1 0
3 4 2 0
15 16 2 0
16 11 1 0
6 7 1 0
14 17 1 0
17 18 1 0
7 8 2 0
8 9 1 0
9 5 2 0
4 6 1 0
1 10 1 0
17 22 1 0
18 19 1 0
19 20 1 0
20 21 1 0
21 22 1 0
5 6 1 0
4 23 1 0
23 24 1 0
10 11 1 0
1 2 2 0
11 12 2 0
5 1 1 0
24 25 2 0
25 26 1 0
26 27 1 0
27 23 2 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 362.40Molecular Weight (Monoisotopic): 362.1604AlogP: 2.09#Rotatable Bonds: 4Polar Surface Area: 96.26Molecular Species: NEUTRALHBA: 8HBD: 2#RO5 Violations: ┄HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 12.81CX Basic pKa: 2.54CX LogP: 1.74CX LogD: 1.74Aromatic Rings: 4Heavy Atoms: 27QED Weighted: 0.57Np Likeness Score: -2.09
References 1. Andrews MJ, Clase JA, Bar G, Tricarico G, Edwards PJ, Brys R, Chambers M, Schmidt W, MacLeod A, Hirst K, Allen V, Birault V, Le J, Harris J, Self A, Nash K, Dixon G.. (2012) Discovery of a series of imidazopyrazine small molecule inhibitors of the kinase MAPKAPK5, that show activity using in vitro and in vivo models of rheumatoid arthritis., 22 (6): [PMID:22342143 ] [10.1016/j.bmcl.2012.01.077 ]